Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
A plant species of the genus STEPHANIA, family MENISPERMACEAE, that contains tetrandrine and bisbenzylisoquinoline alkaloids.
A plant genus of the family FABACEAE. Members contain karanjin. Some species of this genus have been reclassified to other genera of FABACEAE including Callerya, DERRIS and MILLETTIA.
A plant genus of the family AMARANTHACEAE, order Caryophyllales, which has been used in traditional medicine (MEDICINE, CHINESE TRADITIONAL).
The Madder plant family of the order Rubiales, subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.
Substances which lower blood glucose levels.
A plant species of the family VACCINIUM.
The study of the heart, its physiology, and its functions.
A medical specialty concerned with the diagnosis and treatment of SLEEP WAKE DISORDERS and their causes.
The branch of medicine concerned with the evaluation and initial treatment of urgent and emergent medical problems, such as those caused by accidents, trauma, sudden illness, poisoning, or disasters. Emergency medical care can be provided at the hospital or at sites outside the medical facility.
A subspecialty of internal medicine concerned with the study of the physiology and diseases of the digestive system and related structures (esophagus, liver, gallbladder, and pancreas).
A subspecialty of internal medicine concerned with the metabolism, physiology, and disorders of the ENDOCRINE SYSTEM.
A subspecialty of internal medicine concerned with the anatomy, physiology, and pathology of the kidney.
A medical specialty concerned with the study of the structures, functions, and diseases of the nervous system.
An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.
Dilation of an occluded coronary artery (or arteries) by means of a balloon catheter to restore myocardial blood supply.
An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
Compounds that bind to and block the stimulation of PURINERGIC P2Y RECEPTORS. Included under this heading are antagonists for specific P2Y receptor subtypes.
A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.
A subclass of purinergic P2Y receptors that have a preference for ADP binding and are coupled to GTP-BINDING PROTEIN ALPHA SUBUNIT, GI. The P2Y12 purinergic receptors are found in PLATELETS where they play an important role regulating PLATELET ACTIVATION.
An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol.
Cholesterol present in food, especially in animal products.
Substances used to lower plasma CHOLESTEROL levels.
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.
A detailed review and evaluation of selected clinical records by qualified professional personnel to improve the quality of patient care and outcomes. The clinical audit was formally introduced in 1993 into the United Kingdom's National Health Service.
Drugs used to treat or prevent skin disorders or for the routine care of skin.
A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
Voluntary cooperation of the patient in taking drugs or medicine as prescribed. This includes timing, dosage, and frequency.
Errors in prescribing, dispensing, or administering medication with the result that the patient fails to receive the correct drug or the indicated proper drug dosage.
Subset of helper-inducer T-lymphocytes which synthesize and secrete the interleukins IL-4, IL-5, IL-6, and IL-10. These cytokines influence B-cell development and antibody production as well as augmenting humoral responses.
Subset of helper-inducer T-lymphocytes which synthesize and secrete interleukin-2, gamma-interferon, and interleukin-12. Due to their ability to kill antigen-presenting cells and their lymphokine-mediated effector activity, Th1 cells are associated with vigorous delayed-type hypersensitivity reactions.
Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
The detection of long and short term side effects of conventional and traditional medicines through research, data mining, monitoring, and evaluation of healthcare information obtained from healthcare providers and patients.
The number of times the HEART VENTRICLES contract per unit of time, usually per minute.
The small mass of modified cardiac muscle fibers located at the junction of the superior vena cava (VENA CAVA, SUPERIOR) and right atrium. Contraction impulses probably start in this node, spread over the atrium (HEART ATRIUM) and are then transmitted by the atrioventricular bundle (BUNDLE OF HIS) to the ventricle (HEART VENTRICLE).
The decrease in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical.
A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.

Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. (1/1571)

-The clinical efficacy of anthracycline antineoplastic agents is limited by a high incidence of severe and usually irreversible cardiac toxicity, the cause of which remains controversial. In primary cultures of neonatal and adult rat ventricular myocytes, we found that daunorubicin, at concentrations /=10 micromol/L induced necrotic cell death within 24 hours, with no changes characteristic of apoptosis. To determine whether reactive oxygen species play a role in daunorubicin-mediated apoptosis, we monitored the generation of hydrogen peroxide with dichlorofluorescein (DCF). However, daunorubicin (1 micromol/L) did not increase DCF fluorescence, nor were the antioxidants N-acetylcysteine or the combination of alpha-tocopherol and ascorbic acid able to prevent apoptosis. In contrast, dexrazoxane (10 micromol/L), known clinically to limit anthracycline cardiac toxicity, prevented daunorubicin-induced myocyte apoptosis, but not necrosis induced by higher anthracycline concentrations (>/=10 micromol/L). The antiapoptotic action of dexrazoxane was mimicked by the superoxide-dismutase mimetic porphyrin manganese(II/III)tetrakis(1-methyl-4-peridyl)porphyrin (50 micromol/L). The recognition that anthracycline-induced cardiac myocyte apoptosis, perhaps mediated by superoxide anion generation, occurs at concentrations well below those that result in myocyte necrosis, may aid in the design of new therapeutic strategies to limit the toxicity of these drugs.  (+info)

Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2, 2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. (2/1571)

The site of action of 3-(2,2,2-trimethylhydrazinium) propionate (THP), a new cardioprotective agent, was investigated in mice and rats. I.p. administration of THP decreased the concentrations of free carnitine and long-chain acylcarnitine in heart tissue. In isolated myocytes, THP inhibited free carnitine transport with a Ki of 1340 microM, which is considerably higher than the observed serum concentration of THP. The major cause of the decreased free carnitine concentration in heart was found to be the decreased serum concentration of free carnitine that resulted from the increased renal clearance of carnitine by THP. The estimated Ki of THP for inhibiting the reabsorption of free carnitine in kidneys was 52.2 microM, which is consistent with the serum THP concentration range. No inhibition of THP on the carnitine palmitoyltransferase activity in isolated mitochondrial fractions was observed. These results indicate that the principal site of action of THP as a cardioprotective agent is the carnitine transport carrier in the kidney, but not the carrier in the heart.  (+info)

Treatment patterns for heart failure in a primary care environment. (3/1571)

Little published information regarding current pharmacotherapeutic treatment patterns for congestive heart failure (CHF) in nonacademic, ambulatory care settings is available. We sought to assess, in a nonacademic primary care environment, pharmacotherapeutic treatment patterns for CHF with respect to consistency with clinical trial evidence and published treatment guideline recommendations. Over an 18-month period, we examined CHF pharmacotherapy using a computerized, integrated clinical diagnoses and prescription database from an outpatient community healthcare center without academic affiliations. We identified adult patients meeting contact criteria and with diagnosis of CHF by International Classification of Diseases (ICD-9-CM) coding and assessed prescribed therapy as well as select comorbid conditions. Drugs of interest included those with known or suspected benefit or detriment and those with unproven benefit. An eligible group of 14,983 patients was identified, from which a cohort of 148 patients with CHF was selected. Forty-one percent of these 148 patients were prescribed an angiotensin converting enzyme (ACE) inhibitor, 34% digoxin, 12% diuretic, 12% hydralazine + nitrate, 20% inhaled beta-agonists, and 66% warfarin. Only 5% of patients were prescribed the combination of an ACE inhibitor, digoxin, and diuretic. Thirty-one percent had a comorbid diagnosis of atrial fibrillation, of whom 44% were prescribed digoxin, 22% diltiazem, 15% beta-blockers, 15% digoxin and diltiazem, 7% digoxin and a beta-blocker, and 33% warfarin. In general, recommended therapies for CHF appeared underutilized in this cohort, whereas those of unclear benefit and potential detriment appeared overutilized. Although these results may not be readily generalized to the entire healthcare system, they do suggest a need for additional analysis and potential intervention.  (+info)

Antagonism by acetyl-RYYRIK-NH2 of G protein activation in rat brain preparations and of chronotropic effect on rat cardiomyocytes evoked by nociceptin/orphanin FQ. (4/1571)

For the further elucidation of the central functions of nociceptin/orphanin FQ (noc/OFQ), the endogenous ligand of the G protein-coupled opioid receptor-like receptor ORL1, centrally acting specific antagonists will be most helpful. In this study it was found that the hexapeptide acetyl-RYYRIK-NH2 (Ac-RYYRIK-NH2), described in literature as partial agonist on ORL1 transfected in CHO cells, antagonizes the stimulation of [35S]-GTPgammaS binding to G proteins by noc/OFQ in membranes and sections of rat brain. The antagonism of the peptide was competitive, of high affinity (Schild constant 6.58 nM), and specific for noc/OFQ in that the stimulation of GTP binding by agonists for the mu-, delta-, and kappa-opioid receptor was not inhibited. The hexapeptide also fully inhibited the chronotropic effect of noc/OFQ on neonatal rat cardiomyocytes. It is suggested that Ac-RYYRIK-NH2 may provide a promising starting point for in vivo tests for antagonism of the action of noc/OFQ and for the further development of highly active and specific antagonists.  (+info)

Acute anti-ischemic effect of testosterone in men with coronary artery disease. (5/1571)

BACKGROUND: The role of testosterone on the development of coronary artery disease in men is controversial. The evidence that men have a greater incidence of coronary artery disease than women of a similar age suggests a possible causal role of testosterone. Conversely, recent studies have shown that the hormone improves endothelium-dependent relaxation of coronary arteries in men. Accordingly, the aim of the present study was to evaluate the effect of acute administration of testosterone on exercise-induced myocardial ischemia in men. METHODS AND RESULTS: After withdrawal of antianginal therapy, 14 men (mean age, 58+/-4 years) with coronary artery disease underwent 3 exercise tests according to the modified Bruce protocol on 3 different days (baseline and either testosterone or placebo given in a random order). The exercise tests were performed 30 minutes after administration of testosterone (2.5 mg IV in 5 minutes) or placebo. All patients showed at least 1-mm ST-segment depression during the baseline exercise test and after placebo, whereas only 10 patients had a positive exercise test after testosterone. Chest pain during exercise was reported by 12 patients during baseline and placebo exercise tests and by 8 patients after testosterone. Compared with placebo, testosterone increased time to 1-mm ST-segment depression (579+/-204 versus 471+/-210 seconds; P<0. 01) and total exercise time (631+/-180 versus 541+/-204 seconds; P<0. 01). Testosterone significantly increased heart rate at the onset of 1-mm ST-segment depression (135+/-12 versus 123+/-14 bpm; P<0.01) and at peak exercise (140+/-12 versus 132+/-12 bpm; P<0.01) and the rate-pressure product at the onset of 1-mm ST-segment depression (24 213+/-3750 versus 21 619+/-3542 mm Hgxbpm; P<0.05) and at peak exercise (26 746+/-3109 versus 22 527+/-5443 mm Hgxbpm; P<0.05). CONCLUSIONS: Short-term administration of testosterone induces a beneficial effect on exercise-induced myocardial ischemia in men with coronary artery disease. This effect may be related to a direct coronary-relaxing effect.  (+info)

Drug-induced heart failure. (6/1571)

Heart failure is a clinical syndrome that is predominantly caused by cardiovascular disorders such as coronary heart disease and hypertension. However, several classes of drugs may induce heart failure in patients without concurrent cardiovascular disease or may precipitate the occurrence of heart failure in patients with preexisting left ventricular impairment. We reviewed the literature on drug-induced heart failure, using the MEDLINE database and lateral references. Successively, we discuss the potential role in the occurrence of heart failure of cytostatics, immunomodulating drugs, antidepressants, calcium channel blocking agents, nonsteroidal anti-inflammatory drugs, antiarrhythmics, beta-adrenoceptor blocking agents, anesthetics and some miscellaneous agents. Drug-induced heart failure may play a role in only a minority of the patients presenting with heart failure. Nevertheless, drug-induced heart failure should be regarded as a potentially preventable cause of heart failure, although sometimes other priorities do not offer therapeutic alternatives (e.g., anthracycline-induced cardiomyopathy). The awareness of clinicians of potential adverse effects on cardiac performance by several classes of drugs, particularly in patients with preexisting ventricular dysfunction, may contribute to timely diagnosis and prevention of drug-induced heart failure.  (+info)

Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. (7/1571)

1. We investigated the cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor mice. The in vitro pharmacology of these agonists was determined at recombinant (human) alpha2-adrenoceptors and at endogenous (dog) alpha2A-adrenoceptors. 2. In wild-type mice, rilmenidine, moxonidine (100, 300 and 1000 microg kg(-1), i.v.) and clonidine (30, 100 and 300 microg kg(-1), i.v.) dose-dependently decreased blood pressure and heart rate. 3. In D79N alpha2A-adrenoceptor mice, responses to rilmenidine and moxonidine did not differ from vehicle control. Clonidine-induced hypotension was absent, but dose-dependent hypertension and bradycardia were observed. 4. In wild-type mice, responses to moxonidine (1 mg kg(-1), i.v.) were antagonized by the non-selective, non-imidazoline alpha2-adrenoceptor antagonist, RS-79948-197 (1 mg kg(-1), i.v.). 5. Affinity estimates (pKi) at human alpha2A-, alpha2B- and alpha2C-adrenoceptors, respectively, were: rilmenidine (5.80, 5.76 and 5.33), moxonidine (5.37, <5 and <5) and clonidine (7.21, 7.16 and 6.87). In a [35S]-GTPgammaS incorporation assay, moxonidine and clonidine were alpha2A-adrenoceptor agonists (pEC50/intrinsic activity relative to noradrenaline): moxonidine (5.74/0.85) and clonidine (7.57/0.32). 6. In dog saphenous vein, concentration-dependent contractions were observed (pEC50/intrinsic activity relative to noradrenaline): rilmenidine (5.83/0.70), moxonidine (6.48/0.98) and clonidine (7.22/0.83). Agonist-independent affinities were obtained with RS-79948-197. 7. Thus, expression of alpha2A-adrenoceptors is a prerequisite for the cardiovascular effects of moxonidine and rilmenidine in conscious mice. There was no evidence of I1-imidazoline receptor-mediated effects. The ability of these compounds to act as alpha2A-adrenoceptor agonists in vitro supports this conclusion.  (+info)

Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes. (8/1571)

We investigated effects of a novel cardioprotective drug, JTV-519 (4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahy dro-1,4-benzothiazepine monohydrochloride) on membrane currents of guinea pig ventricular myocytes by whole-cell voltage and current clamp methods. The fast Na+ current (iNa) was activated by ramp pulses from various holding potentials of -90, -80 or -60 mV to 10 mV with various intervals. At 0.2 Hz, JTV-519 inhibited iNa in a concentration-dependent manner with an IC50 of approximately 1.2 and 2 microM at the holding potential of -60 and -90 mM, respectively, implicating a voltage-dependent block. Increasing the pulse frequency from 1 to 2 or 3.3 Hz in the presence of 1 microM JTV-519 shortened the time-course and increased the level of iNa block, indicating a frequency-dependent block. The time-course of iNa blocking by JTV-519 was slower than that of lidocaine and similar to that of quinidine. Ca2+ current (iCa) and the inwardly rectifying K+ current (iK1) were also inhibited by JTV-519. JTV-519 decreased the duration and the height of the plateau of the action potential. We conclude that JTV-519 has frequency- and voltage-dependent blocking effects on iNa as well as inhibition of iCa and iK1.  (+info)

Looking for Cardiovascular Agent? Find out information about Cardiovascular Agent. The following article is from The Great Soviet Encyclopedia . It might be outdated or ideologically biased. a medicinal preparation used in the treatment of... Explanation of Cardiovascular Agent
Learn Overview of Cardiovascular Agents - Chapter 6: Cardiovascular Agents - Pharmacotherapeutics for Advanced Nursing Practice, 1st. Ed., Demler & Rhoads, 2018 - Hypotensive Agents for Nursing RN faster and easier with Picmonics unforgettable videos, stories, and quizzes! Picmonic is research proven to increase your memory retention and test scores. Start learning today for free!
Table of Content Chapter 1 Global Cardiovascular Drugs Market: Summary and Quantitative Analysis 1.1 Report Description 1.2 Global Cardiovascular Drugs Market Revenue Overview 1.3 Global Cardiovascular Drugs Market Revenue (USD Billion) and Growth (%) Rate, 2015- 2025 Chapter 2 Global Cardiovascular Drugs Market: Overview and Qualitative Analysis 2.1 Executive Summary 2.2 Market Drivers 2.3 Market Restraints 2.4 Market Opportunities 2.5 Market Trends 2.6 Global Cardiovascular Drugs Market: SWOT Analysis 2.7 Global Cardiovascular Drugs Market: PEST Analysis 2.7 Global Cardiovascular Drugs Market: Porters Five Forces Analysis 2.8 Global Cardiovascular Drugs Market: Attractiveness Analysis 2.8.1 Global Cardiovascular Drugs Market: Attractiveness Analysis by Type 2.8.2 Global Cardiovascular Drugs Market: Attractiveness Analysis by Grade 2.8.3 Global Cardiovascular Drugs Market: Attractiveness Analysis by Regional Chapter 3 Competitive Analysis 3.1 Global Cardiovascular Drugs Market 3.1.1 Global ...
Find Cardiovascular Drugs & Medication manufacturer, Cardiovascular Drugs & Medication supplier, Cardiovascular Drugs & Medication exporter and Cardiovascular Drugs & Medication wholesaler online in India. Call morelife LONDON on +91-8800
Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest and the most important advances in Cardiovascular drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The eBook series should prove to be of interest to all pharmaceutical scientists involved in research in cardiovascular drug design and discovery. Each volume is devoted to the major advances in cardiovascular drug design and discovery. The eBook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field ...
A comprehensive database of more than 10 cardiovascular drug quizzes online, test your knowledge with cardiovascular drug quiz questions. Our online cardiovascular drug trivia quizzes can be adapted to suit your requirements for taking some of the top cardiovascular drug quizzes.
Cardiovascular Drugs Cardiovascular Drugs Cardiovascular Drugs market worldwide is projected to grow by US$7.8 Billion, driven by a compounded growth of 1.4%. Renin-Angiotensin System Blockers, one - Market research report and industry analysis - 12779102
Every medication, basically have some risks or side effect potential. When taking any medication you must look at the benefits versus the risks. If th
Olmesartan Medoxomil & Hydrochlorothiazide Tablets 20mg/12.5mg Product Name : Olmesartan Medoxomil & Hydrochlorothiazide Tablets 20mg/12.5mg Trade Name : Benitec-H, Olmat-H, Olmax H Available Strength : 20mg/ 12.5mg & 40mg/ 12.5mg Available Combination : Olmesartan Medoxomil / Olmesartan Medoxomil, Amlodipine &…. ...
Your doctor will advise you on when to stop taking the cholesterol drug Pravachol (pravastatin). He or she will monitor your cholesterol levels regula
Nurse practitioners can earn pharmacology hours quickly and simply with a live course or from the comfort of home with streaming audio visual presentations. Each features a concise, up-to-date lecture and full slideshow.
Albany, US, 2019-Jul-01 - /EPR Network/ -Cardiovascular drugs are widely used for treating various heart related dysfunction. With increasing number of cardiovascular diseases across the globe is the major driving factor for the growth of the cardiovascular diseases. According to the study conducted by Global Burden of Diseases estimate that the death rate due to CVD is 235 per 100000 in global population. According to WHO, cardiovascular diseases account for 31% deaths globally which is approximately 17.7 million individuals. Out of these 80% of the CVD deaths are due to stroke and heart attacks. Factors such as sedentary lifestyle, excess consumption of alcohol, stress, unhealthy eating habits, smoking are all factors responsible for the increase in the number of cardiovascular disorders among young population too.. Sample Report Access Source The global cardiovascular drugs market report comprises an elaborate executive summary, which includes a market ...
Cardiovascular drug: Cardiovascular drug, any agent that affects the function of the heart and blood vessels. Drugs that act on the cardiovascular system are among the most widely used in medicine. Examples of disorders in which such drugs may be useful include hypertension (high blood pressure), angina pectoris (chest
The journal is essential reading for all researchers involved in cardiovascular drug design and discovery. The journal also covers recent research (where patents have been registered) in fast emerging therapeutic areas/targets & therapeutic agents related to cardiovascular drug discovery.
Choudhry NK, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA, Shrank WH. The implications of therapeutic complexity on adherence to cardiovascular medications [Internet]. Archives of Internal Medicine 2011;171:814-822.
This chapter reviews the basic and clinical pharmacology of cardiovascular drugs; focusing on practical, relevant points related to their pharmacokinetics, mechanisms of action, clinical use, and adverse effects. Despite the large number of available drugs used in the treatment of cardiovascular diseases, the most commonly used drugs are classified under a few categories of agents. The classification used in this chapter is based on the main mechanism of action of the drug. It should be noted that a single class of drugs can be used in treating more than one disease. As clarified in previous chapters, for managing a particular disease, there may be a number of drugs from different classes that can be used either alternatively, in combination, or during a particular stage of a disease. ...
Aims: To continually evaluate the role of cardiovascular drugs in COVID-19 clinical outcomes. Methods: Eligible publications were identified from >500 databases on 1-Nov-2020. One reviewer extracted data with 20% of the records independently extracted
Actiza Pharmaceutical Private Limited - Cardiovascular Drugs, Antibiotics Medicine & Anticancer Injection Exporter from Surat, Gujarat, India
Citation Machine™ helps students and professionals properly credit the information that they use. Cite your congressional publication in Cardiovascular Drugs and Therapy format for free.
Cardiovascular Drugs indications,contraindications,composition,dosage and administration,properties and mode of action,precautions and side effects
Key Companies Covered in the Cardiovascular Drugs Market Research Report are Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, among others.
This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global cardiovascular drugs market across regions.
Ebook How To Relax Blood Vessels :: Garlic health tips cholesterol mtatva health pie, Medical emergencies lesson 5 ppt download, Lifestyles fitness and rehabilitation hypertension ppt, Cardiovascular agents ppt download, Watermelon related sharing tufing com, Sbi3u the circulatory system ppt video online download, Changes after death ppt video online download, Great image of enzymes and amino acids to relax blood vessels, Healthcare arihanthospital more reasons to eat fruit, Amino acids that relax blood vessels free image
Camber Pharmaceuticals manufacturers Losartan, 50 mg- Cozaar Generic- with quality and integrity. A cardiovascular agent used to treat high blood pressure (hypertension) and to help protect the kidneys from damage due to diabetes.
EDITOR-We agree with Epstein that our study was unable to determine whether the participants had been appropriately prescribed cardiovascular drugs. This was not the aim of the study. He says that we may have underestimated the effect of cardiovascular drugs on the risk of falling because doctors may not prescribe these drugs to patients at greatest risk of falling, implying that our estimate of no effect on falls of cardiovascular drugs represents reduced … ...
IV cardiac medication reference pocket card for pressors, beta blockers, calcium channel blockers, and vasodilators. Reference heart rate, systemic vascular resistance, cardiac output, central venous pressure with receptor activation chart. Cardiac Medica
MAJKA COURAGE I NJEZINA DJECA PDF - Get this from a library! Majka Courage i njezina djeca kronika iz tridesetogodišnjeg rata. . Transcript of Majka Courage i njezina djeca. Bertolt Brecht -
Cardiac disease in pregnancy 226Hypertension 228Arrhythmias 238Prosthetic heart valves 244Valvular heart disease 248Congenital heart disease 249Antibiotic prophylaxis peripartum 250Cardiomyopathy 251Ischaemic heart disease 253Cardiac disease is the leading cause of mortality in pregnancy, although overall only small numbers of women are affected. ...
Mouse is widely used in animal testing of cardiovascular disease. However, a large number of cardiovascular drugs that have been experimentally proved to work well on mouse were withdrawn because they caused adverse side effects in human. In this study, we investigate whether binding patterns of withdrawn cardiovascular drugs are conserved between mouse and human through computational dockings and molecular dynamic simulations. In addition, we also measured the level of conservation of gene expression patterns of the drug targets and their interacting partners by analyzing the microarray data. The results show that target proteins of withdrawn cardiovascular drugs are functionally conserved between human and mouse. However, all the binding patterns of withdrawn drugs we retrieved show striking difference due to sequence divergence in drug-binding pocket, mainly through loss or gain of hydrogen bond donors and distinct drug-binding pockets. The binding affinities of withdrawn drugs to their receptors
This is a huge class of drugs, accounting for a huge chunk of the drugs that we actually need to know well, and is one that the NCLEX and USMLE are going to ask you about. Lets break this class down into smaller, more manageable chunks. We will start with drugs used to treat Hypertension, as this class is very large and very important. First of all, take a look at the picture below for a summary of the drugs we will discuss ...
This is a list of changes made recently to pages linked from a specified page (or to members of a specified category). Pages on your watchlist are bold. ...
This is a list of changes made recently to pages linked from a specified page (or to members of a specified category). Pages on your watchlist are bold. ...
Q (Nancy): What is your novel, Faces of Courage, about? And what genre is it?. A (Susan): Faces of Courage is womens Christian fiction. It is the story of a young wife and mother who had a difficult childhood and now faces several difficulties, including an increasingly abusive husband and a cancer diagnosis. She starts out believing herself to lack courage but begins with the help of the Lord and some mentors in her life, to recognize she can find courage at the intersection of faith and grit.. Q: Why did you choose the theme of courage at the intersection of faith and grit?. A: My daughter has been dealing with breast cancer, now deemed metastatic, for several years. Her example of courage during this time inspired me to show readers through the stories I write how to find courage through even the most difficult circumstances.. Q: Tell us about the main character? Was this character hard to write, and why or why not?. A: The main character is Olivia, and she is married to Frank, a former ...
Sanford Children s Hospital is excited to announce the 2006 dates for Camp Courage Day Camp. Scheduled for June 12-16 at Sertoma Park, Camp Courage is a camp for kids with physical disabilities ages 5-14 ...
Courage Country sat down virtually last week with NC Courages sophomore midfielder Milliet to answer our 2020 Starting XI Questions.
Practice Courage - Another competency that leaders need to practice is courage. It is easy to accept what has been accepted. To be the first one to speak up against something is challenging to say the least. Courage also involves the persistence to continue to speak up against something until it is changed. Sometimes courage can feel like a never-ending struggle, ranging from feelings of slow progress, to feeling ignored, to even feeling stigmatized for standing up what you believe in. Sometimes we may not even fully aware of the impact we have on others. There may be people who are listening and who are taking action in silence to make a better tomorrow. This was a lesson Firm learned after he heard of Nicholas action. Courage of conviction, confidence, and persistence to stay the course are what result in positive action ...
Films Media Group, an Infobase Learning Company, is the premier source of high-quality academic streaming video and DVDs for schools, colleges, and libraries.
Health,... Run Walk Roll or Stroll Four ways to get...MINNEAPOLIS July 10 /- 5k Your Way a fundraiserbenefit... Schedule: ... 7-8:30 a.m. Registration (register online before August 1 for $25...,Teams,Forming,for,Courage,Center,5k,Your,Way,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Courage to be Free: Discover Your Original Fearless Self download free PDF and Ebook Writer Guy Finley in English published by RED WHEEL/WEISER
Vulnerability is an act of strength and courage according to the leading researcher on the topic Brene Brown - Jill Chivers and Imogen Lamport discuss
1991 Flower Essences THERAPIST AND CLIENT FIND COURAGE IN MIDST OF PAIN This letter has been a long time coming. It was not possible to write it any sooner as the story was not complete until recently. In my work as a counsellor and flower essence pr...
Providing a physically and emotionally safe environment in which to thrive, Women of Courage courses can provide a catalyst for powerful growth and change.
Vendors talk about the need for transformation, but many companies wait too long to make necessary changes to remain competitive and relevant because they lack the courage to take risks.
Have Courage & Be Kind Use this printable at home or in your office as instant art. Click on the link below to download this free print!
Join and connect with BlackPlanets The Courage to Grow! I WILL NOT LOSE group. Hi, my name is Domonique b.k.a. Nz_Nique20. I wanted to start this group for the I WILL NOT
Today, after weeks of summoning up the courage to come out of the closet to my best friend, I told her I was gay. Immediately after she started...
Mission Statement: The American Journal of Cardiovascular Drugs promotes rational therapy and disease management within the discipline of cardiology by providing a regular program of independent review articles covering all aspects of the management of cardiovascular disorders, particularly the place in therapy of newer and established agents and procedures. ...
The Biomarkers Consortiums In Silico Modeling of Biomarkers of Atherosclerosis: Estimating Risk Reduction and Residual Risk From Statin Therapys goal was to identify a time-dependent, dynamically-responsive panel of extant markers that change in response to Phase II intervention and predict Phase III clinical cardiovascular outcomes to build the model. This model would support cardiovascular drug development decision-making and assessment of atherosclerotic risk in the development of drugs for other indications.. ...
The Biomarkers Consortiums In Silico Modeling of Biomarkers of Atherosclerosis: Estimating Risk Reduction and Residual Risk From Statin Therapys goal was to identify a time-dependent, dynamically-responsive panel of extant markers that change in response to Phase II intervention and predict Phase III clinical cardiovascular outcomes to build the model. This model would support cardiovascular drug development decision-making and assessment of atherosclerotic risk in the development of drugs for other indications.. ...
Susan Acton discovered ACE2 while searching for new cardiovascular drugs. Decades later, she was surprised to see it popping up in the news once COVID took hold.
Agents. 11 (3): 104-10. PMID 9498159. Tousoulis, Dimitris; Stefanadis, Christodoulos (2013-07-29). Biomarkers in Cardiovascular ... patients with a previous cardiovascular event - benefited from the treatment. These people were 39% less likely to die or be ...
82-. ISBN 978-0-8493-4724-5. Dennis V. Cokkinos (6 November 2014). Introduction to Translational Cardiovascular Research. ... Pharmaceutical Chemistry of Antihypertensive Agents. CRC Press. pp. ...
Some agents are more likely to cause complications than others but all sedative agents can cause complications if not used ... Cardiovascular Function. Unaffected. Usually maintained. Usually maintained. May be impaired There is another type of sedation ... Additionally, some agents have antagonists, reversal agents, that can be used to reverse the effects or reduce the amount of ... Sedative agents[edit]. Propofol[edit]. Propofol[5] is a non-barbiturate derivative that is thought to act by stimulating ...
For the cardiovascular system[edit]. *General: β-receptor blockers ("beta blockers"), calcium channel blockers, diuretics, ... antifungal, alkalinizing agents, quinolones, antibiotics, cholinergics, anticholinergics, antispasmodics, 5-alpha reductase ... In the inter-war period, the first anti-bacterial agents such as the sulpha antibiotics were developed. The Second World War ... These were drugs that worked chiefly as anti-anxiety agents and muscle relaxants. The first benzodiazepine was Librium. Three ...
Cardiovascular & Hematological Agents in Medicinal Chemistry. 4 (1): 17-32. doi:10.2174/187152506775268758. PMID 16529547. ... novel agents and therapeutic potential". Cardiovasc Hematol Agents Med Chem. 4 (1): 17-32. doi:10.2174/187152506775268758. PMID ... doi:10.1111/j.1749-6632.1999.tb09388.x. Head, G.; Mayorov, D. (1 January 2006). "Imidazoline Receptors, Novel Agents and ... Bousquet, P (November 2001). "I1 receptors, cardiovascular function, and metabolism". American Journal of Hypertension. 14 (11 ...
Cardiovascular & Hematological Agents in Medicinal Chemistry. 7 (1): 82-90. doi:10.2174/187152509787047676. PMID 19149547. ... Jacoby GA, Tran J (July 1999). "Sequence of the MIR-1 beta-lactamase gene". Antimicrobial Agents and Chemotherapy. 43 (7): 1759 ... Since the tumor results from undifferentiated cells, agents that promote differentiation hold promise as possible therapies. A ... Cardiovascular Research. 84 (3): 434-41. doi:10.1093/cvr/cvp232. PMID 19581315. Takaya T, Ono K, Kawamura T, Takanabe R, Kaichi ...
Discontinuation of these agents is recommended immediately after detection of pregnancy and an alternative medication should be ... In the same study, no reduction in the rate of cardiovascular events (including death) was shown. In one study of people ... April 2010). "Effect of valsartan on the incidence of diabetes and cardiovascular events". The New England Journal of Medicine ... Khalil P, Kabbach G, Said S, Mukherjee D (2018). "Entresto, a New Panacea for Heart Failure?". Cardiovascular & Hematological ...
Yeung J, Holinstat M (July 2011). "12-lipoxygenase: a potential target for novel anti-platelet therapeutics". Cardiovascular & ... HETE metabolic pathway has dual functions in promoting or inhibiting platelet responses depending on the stimulating agent and ... Hematological Agents in Medicinal Chemistry. 9 (3): 154-64. doi:10.2174/187152511797037619. PMC 3171607. PMID 21838667. ...
Yakhontov LN, Liberman SS (March 1987). "Agents for the treatment of cardiovascular diseases". Pharmaceutical Chemistry Journal ...
Therapeutic potential of chalcones as cardiovascular agents. Life sciences, 148, 154-172. DOI: ... Xia, Yi; Yang, Zheng-Yu; Xia, Peng; Bastow, Kenneth F.; Nakanishi, Yuka; Lee, Kuo-Hsiung (2000). "Antitumor agents. Part 202: ... Some 2′-amino chalcones have been studied as potential antitumor agents. The therapeutic (anti-cancer, anti-bacterial, anti- ... Chalcones are the promising candidates in inhibiting various cardiovascular, hematological and anti-obesity targets like ...
Volume 3: Cardiovascular Agents and Endocrines (6th ed.). Wiley. pp. 55-154. ISBN 978-0471370291. "Triamterene and ... Smith Kline & French launched it as a single agent under the brand Dyrenium in 1964. The combination drug with ... Fink CA, McKenna JM, Werner LH (2003). "Diuretic and Uricosuric Agents". In Abraham DJ (ed.). Burger's medicinal chemistry and ... Crosley AP, Ronquillo LM, Strickland WH, Alexander F (February 1962). "Triamterene, a new natruretic agent. Preliminary ...
Volume 3: Cardiovascular Agents and Endocrines (6th ed.). Hoboken, N.J.: Wiley. ISBN 9780471270904. "Merck's Plendil ( ...
Hypoxia, acidosis, hyperkalemia are also negative inotropic agents. Cardiovascular System Dynamics Society Betts, J. Gordon ( ... The heart functions as a pump and acts as a double pump in the cardiovascular system to provide a continuous circulation of ... The cardiovascular centres receive input from a series of visceral receptors with impulses traveling through visceral sensory ... The cardiovascular centres monitor these increased rates of firing, suppressing parasympathetic stimulation or increasing ...
Berne RM (January 1993). "Adenosine--a cardioprotective and therapeutic agent". Cardiovascular Research. 27 (1): 2. doi:10.1093 ...
Endothelial dysfunction has also been shown to be predictive of future adverse cardiovascular events, and is also present in ... These pro- and antiangiogenic signals including integrins, chemokines, angiopoietins, oxygen sensing agents, junctional ... Reriani MK, Lerman LO, Lerman A (June 2010). "Endothelial function as a functional expression of cardiovascular risk factors". ... Blake GJ, Ridker PM (October 2002). "Inflammatory bio-markers and cardiovascular risk prediction". Journal of Internal Medicine ...
Some of these agents appear to protect against cardiovascular complication. Jan Aaseth has since the 1970s been interested in ... Protective measures include the therapeutic use of new iron chelating agents, which have been studied by Aaseth and co-workers ... Aaseth has studies the effects of disease-modifying agents including anti-TNF-alpha drugs and also selenium compounds. ... Analyst, 123(1), 3-6. Aaseth J (1983). Recent advance in the therapy of metal poisonings with chelating agents. Human ...
"Comprehensive review of cardiovascular toxicity of drugs and related agents". Medicinal Research Reviews. 38 (4): 1332-1403. ... Risk of overdose is increased in patients taking multiple serotonergic agents or interacting agents. Symptoms of SNRI overdose ... Agents with dual serotonin and norepinephrine reuptake inhibition (SNRIs) are sometimes called non-tricyclic serotonin and ... It is recommended to washout 4 to 5 half-lives of the serotonergic agent before using an MAO inhibitor. Some studies suggest ...
A Promising KATP Channel Activating Agent". Cardiovascular Drug Reviews. 18: 25. doi:10.1111/j.1527-3466.2000.tb00031.x. v t e ...
"Cardiovascular Pathology Index Images". The Internet Pathology Laboratory for Medical Education. Florida State University ... Brook I (April 2009). "Pericarditis caused by anaerobic bacteria". International Journal of Antimicrobial Agents. 33 (4): 297- ... European Heart Journal Cardiovascular Imaging. 17 (6): 707. doi:10.1093/ehjci/jew056. PMID 27044912. Atallah PC, Kassier A, ... The classic sign of pericarditis is a friction rub heard with a stethoscope on the cardiovascular examination, usually on the ...
Tanaka SK, Villano S (September 2016). "In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline". ... Antimicrobial Agents and Chemotherapy. 58 (2): 1127-35. doi:10.1128/AAC.01242-13. PMC 3910882. PMID 24295985. Flarakos J, Du Y ... Antimicrobial Agents and Chemotherapy. 58 (3): 1279-83. doi:10.1128/AAC.01066-13. PMC 3957880. PMID 24041885. Noel GJ, Draper ... Antimicrobial Agents and Chemotherapy. 60 (9): 5247-53. doi:10.1128/AAC.00320-16. PMC 4997885. PMID 27324778. Villano S, ...
The QTc interval is longer in females, as well as having a stronger response to IKr-blocking agents. In males, the presence of ... Cardiovascular Electrophysiology. 6 (10 Pt 2): 920-36. doi:10.1111/j.1540-8167.1995.tb00368.x. PMID 8548113. S2CID 23136846. ... Dofetilide Ibutilide Ibutilide differs from other class III antiarrhythmic agents in that it activates the slow, delayed inward ... Ziprasidone SSRIs An EKG is recommended before patients are prescribed SSRI agents citalopram and escitalopram if the ...
... is an anti-anginal and anti-arrhythmic agent. Ranade, Vasant V.; Wolf, Marion E.; Mosnaim, Aron D. (November 1995 ... "Section Review: Cardiovascular & Renal: Developments in antiarrhythmic drugs: An overview". Expert Opinion on Investigational ...
CO may play a role as potential therapeutic agent. In mammals, carbon monoxide is naturally produced by the action of heme ... Wang XB, Jin HF, Tang CS, Du JB (16 Nov 2011). "The biological effect of endogenous sulfur dioxide in the cardiovascular system ... Tian H. (Nov 2014). "Advances in the study on endogenous sulfur dioxide in the cardiovascular system". Chin Med J. 127 (21): ... Endogenous sulfur dioxide is also a potent antiinflammatory, antioxidant and cytoprotective agent. It lowers blood pressure and ...
Mathur, P. P. (1972). "Cardiovascular effects of a newer antiarrhythmic agent, disopyramide phosphate". American Heart Journal ... It is a sodium channel blocker and therefore classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative ... Disopyramide does not act as a blocking agent for beta or alpha adrenergic receptors, but does have a significant negative ... These concerns about the drug must be viewed from the clinical perspective that disopyramide is generally the last agent that ...
Syed YY (August 2016). "Idarucizumab: A Review as a Reversal Agent for Dabigatran". American Journal of Cardiovascular Drugs. ...
The symptoms of norbormide were very similar to the better known Ca2+ entry blocker agents. Therefore, norbormide is not only ... Another study has shown that there were respiratory depressions after the cardiovascular effects in the rats which were treated ... Yelnosky J, Lawlor R (September 1971). "Cardiovascular effects of norbormide". European Journal of Pharmacology. 16 (1): 117-9 ... "Norbormide - a Rattus-specific toxic agent". J. Forensic Sci. 1965: 80-83.. ...
Anti-arrhythmic agents used for arrhythmias usually prolong the ERP. For the treatment of atrial fibrillation, it is a problem ... Physiology of the cardiovascular system. Heart. Cardiac output. *Cardiac cycle. *Cardiac output *Heart rate ... that the prolongation of the ERP by these agents also affects the ventricles, which can induce other types of arrhythmias. ...
Abstracts from the 12 International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections. 41: S21. doi: ... International Journal of Antimicrobial Agents. ...
... a novel positive inotropic agent with vasodilating properties". Journal of Cardiovascular Pharmacology. 6 (3): 511-9. doi: ... a structurally novel cardiotonic agent with vasodilating properties". Journal of Cardiovascular Pharmacology. 6 (3): 520-30. ... Phosphodiesterase inhibitor David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN ... Journal of Cardiovascular Pharmacology. 7 (1): 86-90. doi:10.1097/00005344-198501000-00014. PMID 2580156. S2CID 27819870. Daly ...
... s are very important agents in the inflammatory response. Some such as LTB4 have a chemotactic effect on migrating ... Manev, Radmila; Manev, Hari (2004). "5-Lipoxygenase as a Putative Link Between Cardiovascular and Psychiatric Disorders". ... ISBN 978-0-7167-7108-1. Scott JP, Peters-Golden M (September 2018). "Antileukotriene agents for the treatment of lung disease ... Recent research points to a role of 5-lipoxygenase in cardiovascular and neuropsychiatric illnesses. ...
... the choice of an agent depends on the patient's cholesterol profile, cardiovascular risk, and the liver and kidney functions of ... Hypolipidemic agents, cholesterol-lowering drugs or antihyperlipidemic agents, are a diverse group of pharmaceuticals that are ... Investigational classes of hypolipidemic agents: *CETP inhibitors (cholesteryl ester transfer protein), 1 candidate is in ... "Clinical evaluation of lecithin as a lipid-lowering agent". Phytotherapy Research. 9 (8): 597-599. doi:10.1002/ptr.2650090814. ...
... cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review ... A second oral agent of another class or insulin may be added if metformin is not sufficient after three months.[87] Other ... The use of aspirin to prevent cardiovascular disease in diabetes is controversial.[114] Aspirin is recommended in people at ... Krentz AJ, Bailey CJ (February 2005). "Oral antidiabetic agents: current role in type 2 diabetes mellitus". Drugs. 65 (3): 385- ...
Other agents causing ophthalmia neonatorum include Herpes simplex virus (HSV 2), Staphylococcus aureus, Streptococcus ... Cardiovascular. *Pneumopericardium. *Persistent fetal circulation. Haemorrhagic and. hematologic disease. *Vitamin K deficiency ...
... and found a serious cardiovascular adverse reaction rate of about 1 in 1500.[44] This study reported a cardiovascular-related ... The immunosuppressive agents employed in allogeneic transplants for the prevention or treatment of graft-versus-host disease ... For this same group, severe cardiovascular events were observed with a rate of about 1 in 1500. The most common severe adverse ... while requiring high doses of immunosuppressive agents in the early stages of treatment, these doses are less than for ...
Main article: Radiocontrast agent. Contrast radiography uses a radiocontrast agent, a type of contrast medium, to make the ... Angiography is the use of fluoroscopy to view the cardiovascular system. An iodine-based contrast is injected into the ... Contrast agents are required in conventional angiography, and can be used in both projectional radiography and computed ... Quader MA, Sawmiller CJ, Sumpio BE (2000). "Radio Contrast Agents: History and Evolution". Textbook of Angiology. pp. 775-783. ...
Prostate cancer may be treated by removing the major source of testosterone: testicle removal (orchiectomy); or agents which ... Testosterone and the cardiovascular system. *List of steroid abbreviations. *List of androgens/anabolic steroids ...
KC8 is a very strong reducing agent and is pyrophoric and explodes on contact with water.[114][115] While the larger alkali ... ingestion of large amounts of potassium compounds can lead to hyperkalemia strongly influencing the cardiovascular system.[232] ... Their great power as reducing agents makes them very useful in liberating other metals from their oxides or halides.[10]:76 ... Pure alkali metals are dangerously reactive with air and water and must be kept away from heat, fire, oxidising agents, acids, ...
Tikal K, Hrabánková M (June 1993). "[Indications for antidepressive agents in relation to diseases of the cardiovascular system ... No evidence for a possible hepatic or cardiovascular toxicity was found.. History[edit]. Irreversible MAOI antidepressants were ... when cardiovascular toxicity is a concern, SSRIs or the reversible MAOIs such as moclobemide are an option as they lack or have ... moclobemide has been recommended as a first line agent for the treatment of depression in the elderly.[55] Due to the side ...
... oat fiber β-glucan decreases blood levels of LDL cholesterol and so may reduce the risk of cardiovascular diseases.[1] β- ... glucans are used as texturing agents in various nutraceutical and cosmetic products, and as soluble fiber supplements. ...
... and the cardiovascular drug nifedipine.[2] ... Cooling Agent 10. *CPS-369. *Eucalyptol (eucalyptus). * ...
Angiotensin converting enzyme inhibitors, adrenergic agents such as alpha-1 blockers and beta-blockers and alpha-2 agonists, ... Cardiovascular disease (vessels) (I70-I99, 440-456). Arteries, arterioles. and capillaries. Inflammation. *Arteritis *Aortitis ... antiplatelet agents (aspirin and clopidogrel), naftidrofuryl, pentoxifylline, and cilostazol (selective PDE3 inhibitor) are ...
Autonomic Cardiovascular Damage during Post-menopause: the Role of Physical Training. Aging and Disease. 2013, 4 (6): 320-28. ... The STAR Trial: Evidence for Raloxifene as a Breast Cancer Risk Reduction Agent for Postmenopausal Women. J Natl Compr Canc ... Hormone therapy for preventing cardiovascular disease in post-menopausal women. The Cochrane Database of Systematic Reviews. ... Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular ...
... or with a pharmaceutical agent such as methacholine or histamine. ... Unstable cardiovascular status (angina, recent myocardial infarction, etc.). *Thoracic, abdominal, or cerebral aneurysms ...
The JCV virus may also be a causative agent of aseptic meningitis (JCVM), as JCV was the only pathogen identified in the CSF of ... recent literature has identified viral variants as etiological agents of other novel syndromes. For example, JCV has been found ...
"Expert Review of Cardiovascular Therapy. 8 (6): 793-802. doi:10.1586/erc.10.27. PMC 2904515. PMID 20528637.. ... The term "calcium-sparing diuretic" is sometimes used to identify agents that result in a relatively low rate of excretion of ... Alternatively, an antidiuretic, such as vasopressin (antidiuretic hormone), is an agent or drug which reduces the excretion of ... Diuretics increase the urine volume and dilute doping agents and their metabolites. Another use is to rapidly lose weight to ...
Waugh, N; Cummins, E, Royle, P, Clar, C, Marien, M, Richter, B, Philip, S (2010 Jul). "Newer agents for blood glucose control ... "Sugar Sweetened Beverages, Obesity, Type 2 Diabetes and Cardiovascular Disease risk". Circulation 121 (11): 1356-64. doi ... "Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type ...
... long-acting agents are recommended.[2] Long-acting agents partly work by reducing hyperinflation.[74] If long-acting ... "Morbidity & Mortality: 2009 Chart Book on Cardiovascular, Lung, and Blood Diseases" (PDF). National Heart, Lung, and Blood ... External agents/. occupational. lung disease. Pneumoconiosis Aluminosis. Asbestosis. Baritosis. Bauxite fibrosis. Berylliosis. ... Several new long-acting agents are under development.[2] Treatment with stem cells is under study.[201] While there is ...
"Ex-FBI Agent Pleads Guilty in Conflict-of-Interest Case", The Washington Post. February 13, 1996, p. A12. ... cardiovascular and pulmonary toxicity, neurotoxicity, as well as possible human fatalities. There is a risk in using this ... Pepper spray (also known as capsicum spray) is a lachrymatory agent (a chemical compound that irritates the eyes to cause tears ... OC is not the only legal agent used. CS, CR, PAM (МПК), and (rarely) CN are also legal[41] and highly popular. ...
Indian Agent (Canada),Indian Agent]] and eight others.,ref name="finkelconrad"/, Although Big Bear actively opposed the attacks ... efforts to explain between population variation in rates of type 2 diabetes and cardiovascular disease. Cambridge: Cambridge ... British agents worked to make the First Nations into military allies of the British, providing supplies, weapons, and ... the British agents discouraged any warlike activities or raids on American settlements, but the Americans became increasingly ...
... has reported that inadequate access to advanced cardiovascular technologies is one of the major contributors to cardiovascular ... who have body hair on the chest may want to remove the hair by clipping just prior to surgery or using a depilatory agent ( ... "British Cardiovascular Society". Archived from the original on 2013-12-12. Retrieved 2013-12-29.. ... Sleight later became Professor of Cardiovascular Medicine at Oxford University.[40][41] ...
Cardiovascular diseaseEdit. Accelerated deposition of cholesterol in the walls of arteries leads to atherosclerosis, the ... Heterozygous FH is normally treated with statins, bile acid sequestrants, or other lipid lowering agents that lower cholesterol ... A single abnormal copy (heterozygote) of FH causes cardiovascular disease by the age of 50 in about 40% of cases. Having two ... Having two abnormal copies (being homozygous) may cause severe cardiovascular disease in childhood. Heterozygous FH is a common ...
Cardiovascular: Hypotension, which may be severe. Severe or fatal arrhythmias and heart failure are quite frequent.[9] ... Antiprotozoal agents. *Amidines. *DNA-binding substances. *NMDA receptor antagonists. *Phenol ethers. *World Health ...
... cardiovascular diseases,[120][121][122] inflammatory responses and autoimmune diseases,[123] and systemic DNA damage responses ... is the first proteasome inhibitor to reach clinical use as a chemotherapy agent.[102] Bortezomib is used in the treatment of ... a novel class of potent and effective antitumor agents". Cancer Research. 59 (11): 2615-22. PMID 10363983.. ... inhibitors to induce apoptosis in rapidly dividing cells has been exploited in several recently developed chemotherapy agents ...
"Nicotine as an antiepileptic agent in ADNFLE: An n-of-one study".. ... Benowitz NL, Jacob P 3rd, Jones RT, Rosenberg J (1982). "Interindividual variability in the metabolism and cardiovascular ...
Cardiovascular disease[edit]. A 2013 meta-analysis found no evidence that vitamin C supplementation reduces the risk of ... Ascorbic acid is a common enzymatic cofactor in mammals used in the synthesis of collagen, as well as a powerful reducing agent ... Oxidized forms of the molecule such as dehydroascorbic acid are converted back to ascorbic acid by reducing agents.[3] ... Uric acid and ascorbate are both strong reducing agents. This has led to the suggestion that, in higher primates, uric acid has ...
Scientific Consensus Statement on Environmental Agents Associated with Neurodevelopmental Disorders, The Collaborative on ... and cardiovascular disease (any affliction related to the heart but most commonly the thickening of arteries due to excess fat ...
"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection" (PDF). The Panel on Antiretroviral Therapy and ... e enfermidades cardiovasculares.[128] Non está claro se estas condicións resultan da infección por VIH como tal ou son efectos ... Panel on Antiretroviral Guidelines for Adults and Adolescents (2009-12-01). Guidelines for the use of antiretroviral agents in ... Coovadia H (2004). "Antiretroviral agents-how best to protect infants from HIV and save their mothers from AIDS". N. Engl. J. ...
Several selective antagonists for the PAR1 receptor have been developed, for use as anti-clotting agents for the treatment of ... Leger AJ, Covic L, Kuliopulos A (Sep 2006). "Protease-activated receptors in cardiovascular diseases". Circulation. 114 (10): ...
Mahmood SS (2016). "Cardiovascular Complications of Cranial and Neck Radiation". Current Treatment Options in Cardiovascular ... of the radioactive agents being infused.[15] Methods, techniques and devices are available to lower the occurrence of this type ... Cardiovascular disease. Radiation can increase the risk of heart disease and death as observed in previous breast cancer RT ... Cardiovascular late side effects have been termed radiation-induced heart disease (RIHD) and radiation-induced vascular disease ...
November 2010). "Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for ... Adrenergic storm Alcohol Amphetamine Anaemia Antiarrhythmic agents Anxiety Atrial fibrillation Atrial flutter Atrial ... Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". Circulation. 122 (18 Suppl 3): S729-67. doi:10.1161/ ...
Could certain agents provide cardiovascular benefits as well? ... Diabetes mellitus is a major risk factor for cardiovascular (CV ... Cardiovascular (CV) outcome trials for newer antihyperglycemic agents have shown significant CV benefit of using certain ... CV cardiovascular, CVD cardiovascular disease, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, HbA1c glycated ... CV cardiovascular, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, HF heart failure, MI myocardial infarction, ...
Cardiovascular disease is one of the major causes of morbidity and mortality following solid organ transplantation. Many of the ... Cardiovascular toxicities of immunosuppressive agents Am J Transplant. 2002 Oct;2(9):807-18. doi: 10.1034/j.1600-6143.2002. ... Attention to the potential cardiovascular toxicities of individual immunosuppressive agents may help design strategies for ... Cardiovascular disease is one of the major causes of morbidity and mortality following solid organ transplantation. Many of the ...
Anticoagulants, Cardiovascular. Class Summary. These agents prevent recurrent or ongoing thromboembolic occlusion. ... Diuretic Agents. Class Summary. Diuretics can be useful to reduce the amount of ascites, providing symptomatic relief and ... Antifibrinolytic Agents. Class Summary. Fibrinolytic drugs are used to dissolve a pathologic intraluminal thrombus or embolus ... This agent is often preferred because of its potassium-sparing effects, particularly in a clinical setting that includes ...
have been trying to find current information on Viet Nam Veterans and the effect Agent Orange had on them. My father died in ... My father died in 1991 at age 60 after 2 1/2 years of terrible illness which I attribute to Agent Orange. He was a career ... I have attempted to look online to find a connection between Agent Orange and the hypotension and cannot find any information. ... Im not sure what type of info you are searching for, but if you Google hypotension Agent Orange on the second page there is ...
... Jennifer LaPreze, PharmD, BCACP, CDE, CPP. Atrium Health. Fort Mill ... Cardiovascular Disease and Diabetes. ... Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and ... GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. ...
Cardiovascular, Other. Class Summary. It may be necessary to use antiarrhythmic agents for concomitant tachyarrhythmia. ... Anticholinergic Agents. Class Summary. Atropine, by vagolytic effect, increases the heart rate. Although it may also be used ... Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian ... Justin D Pearlman, MD, PhD, ME, MA Director of Advanced Cardiovascular Imaging, Professor of Medicine, Professor of Radiology, ...
The major cause of death is cardiovascular, and the risk for a myocardial infarction (MI) in a patient with DM who has never ... Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus Am J Cardiovasc Drugs. 2004;4(2):87-106. ... The major cause of death is cardiovascular, and the risk for a myocardial infarction (MI) in a patient with DM who has never ... Review of the major primary prevention trials in DM indicates that a significantly reduced risk for MI or major cardiovascular ...
Cardiovascular AgentsDopamine (Intropin)DOC in patients with clonidine toxicity who remain hypotensive after IVF. Stimulates ... Cardiovascular Agents. Dopamine (Intropin). DOC in patients with clonidine toxicity who remain hypotensive after IVF. ... Which medications in the drug class Cardiovascular Agents are used in the treatment of Clonidine Toxicity?. Updated: May 30, ...
Cardiovascular Medicine, Emergency Medicine, Endocrinology and Diabetes, Family Medicine, Gastroenterology and Hepatology, ...
Hematological Agents. Each issue contains a series of timely in-depth reviews, original research articles and drug clinical ... Hematological Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry ... trial studies written by leaders in the field covering a range of current topics in Cardiovascular & Hematological medicinal ... and rational drug design for the discovery of new Cardiovascular & ...
... combination therapy for type 2 diabetes (RECORD): a ... The primary endpoint was cardiovascular hospitalisation or cardiovascular death, with a hazard ratio (HR) non-inferiority ... We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the ... for cardiovascular death, 1.14 (0.80-1.63) for myocardial infarction, and 0.72 (0.49-1.06) for stroke. Heart failure causing ...
Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome (AReMIS). The safety and scientific ... Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome. ... History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors ...
The presentation of the PLATO study showed that ticagrelor reduced the rate of cardiovascular events from 11.7 percent to 9.8 ... New oral antiplatelet agent ticagrelor first to show reduction in cardiovascular death By Professor L. C. Wallentin ... New oral antiplatelet agent ticagrelor first to show reduction in cardiovascular death. European Society of Cardiology ... In the PLATO study, the reduction in risk of cardiovascular events appears early and the benefit over clopidogrel grows with ...
This review summarizes data on the cardiovascular pharmacological actions of rutaecarpine the published over the recent years, ... Furthermore, it has been reported that rutaecarpine has beneficial effects on some cardiovascular diseases. ... Rutaecarpine has been shown to have cardiovascular biological effects such as inotropic and chronotropic, vasorelaxant, anti- ... aiming to provide more evidence supporting its use in the treatment of cardiovascular diseases. ...
Agent Orange ailments like cardiovascular diseases - LouB. 11/22/2016, 17:00:23 *Re: Agent Orange ailments like cardiovascular ... Agent Orange ailments like cardiovascular diseases - LEONARD 11/22/2016, 4:14:21 *Re: Agent Orange ailments like cardiovascular ... Re: Agent Orange ailments like cardiovascular diseases - LouB. 11/21/2016, 18:42:13 « Back to index , View thread » ... Agent Orange ailments like cardiovascular diseases. Posted by George Volk. on 10/26/2016, 16:52:06. 24.98.179.x. I was there in ...
Continue Learning about Cardiovascular Agent. Cardiovascular Agent Cardiovascular drugs control and treat various heart ...
Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents. This study has been completed. ... Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents. ... Investigational biological agents within 6 months prior to inclusion.. *Any other investigational drug within 1 month or 5 half ... Cardiovascular risk markers [ Time Frame: 0, 3 and 12 months ]. hs-crp, homocystein, SBHG, apolipoprotein B, MBL, PAPP-A. ...
Continue Learning about Cardiovascular Agent. Cardiovascular Agent Cardiovascular drugs control and treat various heart ...
Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & ... Cardiovascular & Hematological Agents in Medicinal Chemistry MEDLINE/PubMed/Index Medicus, BIOSIS Previews, BIOSIS Reviews ...
Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & ... Phytocompounds as Potential Agents to Treat Obesity-Cardiovascular Ailments Volume: 15 Issue: 2 Pp: 104-120 Balaji Meriga*, ... Cardiovascular & Hematological Agents in Medicinal Chemistry MEDLINE/PubMed/Index Medicus, BIOSIS Previews, BIOSIS Reviews ... Polypharmacy in Cardiovascular Medicine: Problems and Promises! Volume: 15 Issue: 1 Pp: 31-39 Mehran Abolbashari*, Tracy E. ...
Home » Role of Oral Agents in Improving Cardiovascular Prognosis in Diabetes Mellitus ... A letter to the editor is presented in response to the article about cardiovascular disease by Pekka Puska in the August 2007 ... Delivering a cardiovascular disease prevention programme in the United Kingdom: translating theory into practice. Lloyd- ... A letter to the editor and a reply are presented in response to the article "Primary and Secondary Prevention of Cardiovascular ...
However, because both agents exert a negative chronotropic effect, their combined ... Cardiovascular Diseases / chemically induced*, drug therapy. Drug Therapy, Combination. Electrophysiology. Female. Humans. Male ... However, because both agents exert a negative chronotropic effect, their combined use may cause bradyarrhythmias with resultant ... Title: Journal of cardiovascular pharmacology Volume: 35 ISSN: 0160-2446 ISO Abbreviation: J. Cardiovasc. Pharmacol. ...
Review: Lipid-lowering agents reduce cardiovascular events in type 2 diabetes. ACP J Club. 2004;141:65. doi: 10.7326/ACPJC-2004 ... Review: Lipid-lowering agents reduce cardiovascular events in type 2 diabetes Apoor S. Gami, MD ... In patients with type 2 diabetes mellitus, do lipid-lowering agents reduce cardiovascular disease (CVD) events? ...
90-minute panel discussion to learn about exciting new research on cardiovascular outcomes studies of antidiabetic agents and ... management paradigm that improve hyperglycemic control while decreasing cardiovascular risk. Watch this expert-led ... guidelines appropriately as well as other strategic insights to improve care for their patients with T2DM and cardiovascular ... Integrate antidiabetic agents with proven cardiovascular safety and efficacy into the management of patients with diabetes to ...
Cardiovascular system Brokerage service for pharmaceutical and parapharmaceutical products active ingredients and precursors.. ... Agents acting on the renin-angiot.. Ace inhibitors, plain Ace inhibitors, plain ... Beta blocking agents Beta blocking agents Beta blocking agents, non-selecti.. Beta blocking agents, selective ... Agents acting on the renin-angiotensin system , ... Cardiovascular system. *Agents acting on the renin-angiotensin ...
Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. Part I: Basic and Clinical Electrophysiologic ... Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. Part II: Hemodynamic Effects and Clinical ... ANTMAN EM, STONE PH, MULLER JE, BRAUNWALD E. Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. Part ... These agents act during the slow inward current of cellular depolarization. The most extensive clinical experience has been ...
ultrasound contrast agents. Ultrasound contrast agents (UCAs) have been in the echocardiographic "toolbox" for many years. Two ... JACC: Cardiovascular Imaging. Volume 3, Issue 9, September 2010 DOI: 10.1016/j.jcmg.2010.07.007 PDF Article ... JACC: Cardiovascular Imaging Sep 2010, 3 (9) 944-946; DOI: 10.1016/j.jcmg.2010.07.007 ... JACC: Cardiovascular Imaging Sep 2010, 3 (9) 944-946; DOI: 10.1016/j.jcmg.2010.07.007 ...
Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, ... Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, ... To our knowledge this is the first study to assess the long term cardiovascular effects of oral antidiabetic agents in non- ... Patients taking pharmacological agents with known effects on the cardiovascular system, glucose metabolism, or insulin ...
Cardiovascular risks associated with secondline oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a ... Home » Blog » News » Cardiovascular risks associated with secondline oral antidiabetic agents added to metformin in patients ...
  • Dr Mukherjee has been an invited lecturer at several major national and international meetings, has authored over 450 publications, edited eighteen textbooks on cardiovascular diseases and written more than 100 textbook chapters. (
  • He received his MD in 1982, from the Baku Medical University (former USSR) with cum laude and PhD in Cardiovascular Diseases from the prestigious Russian Academy of the Medical Sciences, Moscow, Russia in 1988 with cum laude. (
  • Many studies indicate that traditional Chinese herbs are beneficial in the prevention and treatment of cardiovascular diseases. (
  • Furthermore, it has been reported that rutaecarpine has beneficial effects on some cardiovascular diseases. (
  • This review summarizes data on the cardiovascular pharmacological actions of rutaecarpine the published over the recent years, aiming to provide more evidence supporting its use in the treatment of cardiovascular diseases. (
  • It is therefore, of interest to compare the presence of cardiovascular disease in these two inflammatory skin diseases. (
  • A letter to the editor and a reply are presented in response to the article "Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach. (
  • A letter to the editor is presented regarding the association of acute cholecystitis and cardiovascular system diseases. (
  • They had expertise in the use of biological agents for the treatment of rheumatic diseases. (
  • The 128 rheumatologists and bioscientists who attended the consensus conference were chosen from a worldwide group of physicians and other scientists from 20 countries with expertise in the use of biological agents for the treatment of rheumatic diseases. (
  • Consistent evidence has shown an important role of emotional stress in pathogenesis of cardiovascular diseases. (
  • Oxidative stress and inflammation are inter-reliant processes involved in cardiovascular diseases and cancers ( 5 , 6 ), along with apoptosis ( 7 , 8 ) and necrosis ( 9 ). (
  • Aim The aim of this study was to examine the risk of cardiovascular diseases among users of both inhaled (ipratropium bromide or tiotropium bromide) and oral (oxybutynin and propantheline, solifenacin, tolterodine) anticholinergics. (
  • This review examines the use of combinations of oral antiplatelet agents with oral anticoagulant agents for long-term secondary prevention in patients with cardiovascular diseases such as myocardial infarction (MI), mechanical valve replacement, coronary artery stent implantation, and chronic atrial fibrillation (AF). (
  • Contec Global, a multinational conglomerate has concluded arrangement to collaborate with a world class Health Managers and Specialists based in Dubai, United Arab Emirates (UAE), to address the current wave of heart and cardiovascular related diseases in the country by setting up similar Hospital and Research Centre in Abuja. (
  • Biomarkers in Cardiovascular Diseases. (
  • 3 A 2005 Cochrane review of 29 randomized trials that compared metformin to lifestyle modification or to other antiglycemic agents (including sulfonylureas and thiazolidinediones [TZDs]) showed a benefit of metformin monotherapy across multiple outcomes such as glycemic control, all-cause mortality, and incidence of MI, with obese patients experiencing greater benefit compared with overweight patients. (
  • 7 To comply with this guidance, the era of CV outcomes trials (CVOTs) began, increasing the cost and the scope of research required for the approval of new antidiabetic agents. (
  • Of the numerous CVOTs that have been published, results vary widely from noninferiority to superiority of the agent compared to treatment with placebo when assessing CV outcomes. (
  • Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. (
  • We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. (
  • PLATO was a head-to-head outcomes study of ticagrelor plus aspirin versus the active comparator, clopidogrel plus aspirin, and was designed to establish whether ticagrelor could achieve meaningful cardiovascular endpoints in ACS patients. (
  • Watch this expert-led 90-minute panel discussion to learn about exciting new research on cardiovascular outcomes studies of antidiabetic agents and the resultant practical applications for patient care. (
  • Eisai Announces Long-Term Cardiovascular Outcomes Data fo. (
  • Eisai Inc. announced today that results from the CAMELLIA-TIMI 61 cardiovascular (CV) outcomes trial in patients treated with BELVIQ® (lorcaserin HCl) CIV 10 mg twice-daily were presented at the European Society of Cardiology (ESC) Congress 2018 and concurrently published in the New England Journal of Medicine. (
  • Medline, Embase, and the Cochrane Library were searched up to February 2018 for studies reporting on cardiovascular outcomes with macrolides. (
  • Outcomes were pooled using random-effects models and odds ratios (OR), and 95% confidence intervals (CI) were calculated for arrhythmia, cardiovascular death, and myocardial infarction (MI). (
  • The goal of the trial was to evaluate the effect of rosiglitazone plus metformin or sulfonylurea compared with metformin plus sulfonylurea on cardiovascular (CV) outcomes in patients with type 2 diabetes who had inadequate glycemic control while receiving metformin or sulfonylurea monotherapy. (
  • Anemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in patients with chronic kidney disease (CKD). (
  • This meta-analysis was dominated by three large multicenter randomized trials: the "Normal Hematocrit Study" [ 4 ] (NHS, n = 1233), which enrolled patients receiving hemodialysis, the "Correction of Hemoglobin and Outcomes In Renal insufficiency" study (5) (CHOIR, n = 1432) and the "Cardiovascular Risk reduction by Early Anaemia Treatment with Epoietin beta" study [ 6 ] (CREATE, n = 603) both conducted in patients with CKD not receiving dialysis. (
  • SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? (
  • While the modest reduction in the primary composite outcome of myocardial infarction, stroke or cardiovascular death in the EMPA-REG Outcomes trial was welcome, the 30-40% reductions in heart failure hospitalisation (HFH) and cardiovascular and all-cause deaths in patients treated with empagliflozin were highly impressive and unexpected. (
  • In this review, we discuss briefly why cardiovascular endpoint trials for new diabetes agents are required and describe the results of the first four such trials to have reported, as a precursor to understanding why the EMPA-REG Outcomes results came as a surprise. (
  • Few trials of glucose-lowering drugs or strategies in people with type 2 diabetes have investigated cardiovascular outcomes, even though most patients die from cardiovascular causes despite the beneficial effects of lipid-reducing and blood pressure-lowering treatments. (
  • The major cause of death is cardiovascular, and the risk for a myocardial infarction (MI) in a patient with DM who has never had a MI is the same as a nondiabetic individual who has already had one. (
  • HR was 0.84 (0.59-1.18) for cardiovascular death, 1.14 (0.80-1.63) for myocardial infarction, and 0.72 (0.49-1.06) for stroke. (
  • Although the data are inconclusive about any possible effect on myocardial infarction, rosiglitazone does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs. (
  • For several of those CMR protocols, such as myocardial perfusion imaging, MR angiography, or noninvasive tissue characterization, gadolinium-based contrast agents are necessary. (
  • The primary outcome will be a composite of all-cause mortality, non fatal stroke, non fatal myocardial infarction and hospitalization for cardiovascular causes. (
  • These agents may also elicit important indirect effects by an anti-ischemic action referable to both coronary arterial dilation and reduction in myocardial oxygen demand, as well as a baroreceptor-mediated reflex increase in beta adrenergic tone in response to vasodilation. (
  • Procoralan's effects are selective to the sinus node and the new agent has no effect on intracardiac conduction, myocardial contractility or ventricular repolarization. (
  • The future growth of CE is dependent on US Food and Drug Administration (FDA) approval of more US contract agents, as well as on reimbursement, currently only given for left ventricular (LV) cavity opacification at rest, and not for either interpretation of studies or myocardial perfusion assessment. (
  • The only current US Food and Drug Administration (FDA)-approved indication for US contrast agents in the USA is LV endocardial border delineation in patients where two or more myocardial segments are not vizualised on routine echocardiography at rest. (
  • Middle-aged individuals with type 2 diabetes who have yet to develop cardiovascular disease (CVD) events have been reported to have the same risk of fatal or nonfatal myocardial infarction as those without diabetes who have already experienced CVD events ( 4 ). (
  • Cardiovascular disease is one of the major causes of morbidity and mortality following solid organ transplantation. (
  • In conclusion, convincing and increasing evidence is supporting that psoriasis induce accelerated atherosclerosis and hence cardiovascular disease and mortality. (
  • The premature development of T2DM involves problems with multiple organs, including cardiovascular and renal impairment, leading to much earlier mortality and morbidity in affected individuals. (
  • Macrolide use was not associated with the risk of arrhythmia or cardiovascular mortality. (
  • Our findings indicate that macrolide antibiotics as a group are associated with a significant risk for MI but not for arrhythmia and cardiovascular mortality. (
  • Cardiovascular disease (CVD) is the major cause of morbidity and mortality for individuals with diabetes and is the largest contributor to the direct and indirect costs of diabetes. (
  • In order to decrease associated morbidity and mortality, interprofessional team members must enhance their knowledge regarding the effects of inhaled anesthetics on the cardiovascular system. (
  • 16 Moreover, in 207 women with normal glucose tolerance, impaired glucose tolerance, or type 2 diabetes mellitus, low plasma leptin predicted cardiovascular mortality during a 7-year follow-up period. (
  • The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin. (
  • Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study. (
  • It also increases mortality risk from non-cardiovascular causes, including premature death from cancers. (
  • Fortunately, cardiovascular and mortality risks have declined over recent decades, due to reductions in atherogenic lipids, blood pressure and smoking rates, and better glycaemia management. (
  • Notably, the results of recent trials comparing intensive glucose control with standard control led to some concern that aggressive lowering of glucose levels in some individuals may increase short-term mortality, as seen in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study [ 3 ], even though meta-analyses of such trials did confirm a modest reduction in coronary events. (
  • Diabetes mellitus is a major risk factor for cardiovascular (CV) disease. (
  • Although initially designed to keep potentially harmful anti-hyperglycemic agents off the market, the CV outcome trials have provided clinicians with a new set of anti-hyperglycemic drugs with proven CV benefit in patients with diabetes and CV disease, thus expanding the field of CV secondary prevention. (
  • It is therefore essential that clinicians familiarize themselves with the implications of diabetes and provide comprehensive therapeutic strategies to reduce the risk of cardiovascular (CV) events in their diabetic patients. (
  • In the United States, diabetes mellitus remains a significant risk factor for the development of and death from cardiovascular disease (CVD). (
  • In the United States, at least 68% of individuals aged 65 years and older with diabetes die from some form of cardiovascular disease (CVD). (
  • Metformin appears to have potential atherosclerotic cardiovascular disease (ASCVD) benefit, based upon the results of the landmark UK Prospective Diabetes Study. (
  • It is known that patients suffering from psoriasis have increased prevalence of traditional cardiovascular risk factors, such as hypertension, dyslipidaemia, obesity, tobacco use and diabetes mellitus. (
  • In patients with type 2 diabetes mellitus, do lipid-lowering agents reduce cardiovascular disease (CVD) events? (
  • New therapeutic options have emerged in the type 2 diabetes (T2DM) management paradigm that improve hyperglycemic control while decreasing cardiovascular risk. (
  • Type 2 diabetes mellitus (T2DM), obesity, and cardiovascular disease (CVD) share a common pathogenic mechanism. (
  • RESEARCH DESIGN AND METHODS -Using American Diabetes Association (ADA) guidelines, we evaluated the control of cardiovascular disease (CVD) risk factors in 1,372 patients receiving medical care at two major urban medical centers in Brooklyn and Detroit. (
  • Numerous studies have shown the efficacy of controlling individual cardiovascular risk factors in preventing or slowing CVD in people with diabetes. (
  • Patients with type 2 diabetes mellitus (T2DM) have an increased risk of cardiovascular disease (CVD). (
  • Cardiovascular risk in the spectrum of type 2 diabetes mellitus. (
  • Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. (
  • 10,11 Relationships among obesity, metabolic syndrome, diabetes mellitus, and their cardiovascular complications are well established. (
  • The prevalence of diabetes is increasing rapidly, and individuals with diabetes are at high risk for cardiovascular disorders. (
  • The purpose of this review is to summarize the effect of diabetes and glucose lowering agents on restenosis. (
  • The purpose of this review is to summarize the influence of diabetes on coronary restenosis and to summarize the effect of glucose lowering agents on restenosis and outcome. (
  • Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease. (
  • Metformin is the first-line oral agent in the treatment of type 2 diabetes and has many established benefits, including the reduction of macrovascular complications of diabetes. (
  • Nearly 80% of people with diabetes will die as a result of cardiovascular disease (CVD). (
  • 5 Diet, exercise, smoking cessation, and obesity management are also crucial to reducing the cardiovascular burden of people with diabetes, but the focus of this article is on current best practices with therapeutic drug modalities. (
  • Patients with diabetes have lipid abnormalities that place them at a high risk for cardiovascular and cerebrovascular events. (
  • Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. (
  • However, results of the post-trial follow-up of the UK Prospective Diabetes Study, and of a meta-analysis of the four glucose-lowering outcome trials completed to date, suggest about a 15% cardiovascular relative risk reduction per 1% decrement in HbA1c. (
  • The 2008 US Food and Drug Administration industry guidance for licensing of antidiabetic drugs greatly increased the number of cardiovascular outcome trials in diabetes, but most trials opted for non-inferiority designs aiming primarily to show absence of cardiovascular toxicity in the shortest possible time. (
  • In this Series paper, we summarise randomised controlled cardiovascular outcome trials in type 2 diabetes, provide an overview of ongoing trials and their limitations, and speculate on how future trials could be made more efficient and effective. (
  • Dr Malik on new agents in Diabetes - when should I take them? (
  • When should I take the new agents in Diabetes? (
  • Which medications in the drug class Cardiovascular Agents are used in the treatment of Clonidine Toxicity? (
  • We hypothesized that a pulmonary exposure to AgNP induces cardiovascular toxicity influenced by inflammation and vascular dysfunction resulting in expansion of cardiac I/R Injury that is sensitive to particle size and the capping agent. (
  • Most of the nerve agents were originally synthesized in a search for insecticides, but because of their toxicity, they were evaluated for military use. (
  • He presently serves on several journal editorial boards, is the Editor-in-Chief of the Cardiovascular and Hematological Agents in Medicinal Chemistry, and the Cardiology Reviews and is an Associate Editor for the journal Cardiovascular & Hematological Disorders-Drug Targets. (
  • Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. (
  • ANTMAN EM, STONE PH, MULLER JE, BRAUNWALD E. Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. (
  • Health benefits of white tea include a potentially reduced risk of cancer , cardiovascular disorders, and an improvement in oral health. (
  • Flavonoids found in various food products such as white tea, fruits , and vegetables are associated with decreased risk of cardiovascular disorders. (
  • Some agents in particular have raised additional concerns regarding specific conditions, including heart-failure risk. (
  • However, some studies have raised additional concerns with specific agents in relation to other CV results, such as worsening of heart failure. (
  • AIMS: The aim of this study was to assess long-term safety of intravenous cardiovascular agents-vasodilators, inotropes and/or vasopressors-in acute heart failure (AHF). (
  • Preliminary data suggest that certain calcium inhibiting agents may be useful in the vasodilator therapy of congestive heart failure. (
  • 45 ml/min/kg), but evidence of cardiovascular disease, heart failure, and some albuminuria. (
  • At the World Congress of Cardiology in September 2006 the Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) a phase III randomized, double-blind, placebo-controlled clinical trial involving some 2408 patients in 7 countries with left ventricular ejection fraction of 30% or less, reported that only one subgroup - patients with a previous cardiovascular event - benefited from the treatment. (
  • To study the long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance. (
  • The use of oral antidiabetic agents for the prevention of cardiovascular complications in non-diabetic African Americans with insulin resistance needs to be critically evaluated. (
  • 6 Interventions that may improve insulin sensitivity include lifestyle and dietary modification, weight reduction, exercise, and treatment with oral antidiabetic agents. (
  • Comprehensive CV risk reduction in DM should focus on aggressive management of glycemic status, blood pressure, and lipids, the use of antithrombotic agents, as well as therapeutic lifestyle modification including regular physical activities and prudent diet. (
  • In specific, we found dual eligibility enrollment to be associated with a lower likelihood of noncompliance with cardiovascular agent use for each therapeutic class we studied. (
  • Particular emphasis is given to insights derived from therapeutic interventions with lifestyle modification, cardiovascular drugs, antidiabetic drugs, and other related treatments. (
  • Some commonly used pesticides (for example, the organophosphate (OP) Malathion and the carbamate Sevin) and some common therapeutic drugs (the carbamates pyridostigmine [Mestinon] and physostigmine [Antilirium]) also inhibit acetylcholinesterase and can be considered 'nerve agents. (
  • In other aspects of the invention, therapeutic agents may be delivered and/or a seal may be formed about the prosthesis to prevent a Type I failure. (
  • Objectives The purpose of this study was to assess the frequency, manifestation, and severity of acute adverse reactions associated with administration of several gadolinium-based contrast agents to patients who underwent cardiac magnetic resonance (CMR) imaging in the EuroCMR (European Cardiovascular Magnetic Resonance) Registry multinational and multicenter setting. (
  • Studies reporting an increased risk for cardiac toxicities with macrolide antibiotics have raised concern regarding their cardiovascular safety. (
  • We sought to assess the cardiac safety of macrolide antibiotics as a class and of the individual agents by conducting a systematic review and network meta-analysis. (
  • Exposure to both 20 and 110 nm AgNP resulted in exacerbation cardiac I/R injury 1 day following IT instillation independent of capping agent with 20 nm AgNP inducing marginally greater injury. (
  • Conclusions: Exposure to AgNP may result in vascular dysfunction, a potentially maladaptive sensitization of the immune system to respond to a secondary insult (e.g., cardiac I/R) which may drive expansion of I/R injury at 1 and 7 days following IT instillation where the extent of injury could be correlated with capping agents and AgNP size. (
  • The hemodynamic effects of calcium blocking agents are a composite of the various direct and indirect cardiac and peripheral vascular actions of these drugs on the individual determinants of left ventricular pump function. (
  • Nevertheless, the direct negative inotropic effects of these agents have resulted in clinically evident decompensation in cardiac performance in patients with advanced left ventricular dysfunction, and caution is warranted in the application of calcium blocking agents in this setting. (
  • Procoralan is the first pure heart rate-lowering agent and acts by selective inhibition of the cardiac pacemaker If current that controls the spontaneous diastolic depolarization in the sinus node and regulates heart rate. (
  • Cardiovascular agents include cardiac glycosides, vasodilators, and vasoconstrictors. (
  • It will be of interest to busy specialist physicians in cardiovascular medicine, cardiac and vascular surgery, and critical care, as well as primary care physicians and hospitalists who care for patients with these syndromes. (
  • Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a group of pharmaceuticals that are used to suppress abnormal rhythms of the heart (cardiac arrhythmias), such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation. (
  • Class I agents are grouped by what effect they have on the Na+ channel, and what effect they have on cardiac action potentials. (
  • abstract = "Amlodipine, a cardiovascular drug, exhibited remarkable antibacterial action in vitro against 504 bacterial strains belonging to both Gram positive and Gram negative genera, as well as in vivo against a mouse-virulent bacterium. (
  • Thought you might appreciate this item(s) I saw at Journal of Cardiovascular Pharmacology. (
  • Although related organophosphate chemicals are used in medicine, pharmacology, and agriculture, these are not as toxic as the nerve agents. (
  • Attention to the potential cardiovascular toxicities of individual immunosuppressive agents may help design strategies for maintenance of immunosuppression tailored to individual patients. (
  • However, most of the anticancer drugs display a wide array of cardiovascular toxicities, leading to interruption of cancer therapies and maladaptive remodeling in hearts, affecting the short- and long-term quality of life ( 2 - 4 ). (
  • VASOTEC is effective alone or in combination with other antihypertensive agents, especially thiazidetype diuretics . (
  • It may be used alone or in combination with other antihypertensive agents. (
  • Guanethidine is a potent antihypertensive agent for moderate to severe hypertension. (
  • Objective: To evaluate the association between lipid-lowering agents, antihypertensive medications, and colorectal cancer risk. (
  • Review of the major primary prevention trials in DM indicates that a significantly reduced risk for MI or major cardiovascular events may be obtained by enteric-coated aspirin, 81-325 mg/day. (
  • A new study has found that women who gave birth following fertility treatment had no long-term increased risk of death or major cardiovascular events compared to women who gave birth without fertility therapy. (
  • This would logically explain an increased rate of cardiovascular events, but even when adjusting for theses risk factors, psoriasis carry an independent risk for developing cardiovascular disease. (
  • Hypothesis: That the risk of developing cardiovascular disease and especially coronary artery disease is increased in psoriasis patients and that this process can be influenced by treatment of psoriasis with biological treatment. (
  • At present, however, it would appear that the direct negative inotropic and chronotropic actions of the calcium antagonists are offset by the reflex increase in beta adrenergic tone, in combination with the reduction in afterload produced by the peripheral vascular effects of these agents. (
  • The microbubbles in these agents do not aggregate, are biologically inert and safe, 3,4 remain entirely within the vascular space, 5,6 have an intravascular rheology that is similar to that of erythrocytes, 5-7 respond non-linearly to US 8-10 and are eliminated from the body via the reticuloendothelial system with their gas escaping from the lungs. (
  • In this study we investigated whether the use of an elastin-binding contrast agent would allow the detection of vascular remodeling in a mouse model of carotid artery injury and whether it would facilitate the detection of impaired ECM formation in CRP2-/- mice. (
  • He is the Director of the Vascular Diagnostic Laboratory, Harvard Medical School and is the , Harvard Medial School and is the Associate Cardiovascular Fellowship Director at Beth Israel Deaconess Medical Center. (
  • This heightened awareness of potentially harmful CV effects of otherwise effective hypoglycemic drugs resulted in regulatory mandates for CV outcome trials to ascertain the safety of newer anti-hypoglycemic agents appearing on the market. (
  • Cardiovascular drugs control and treat various heart conditions. (
  • Since G protein coupled receptors (GPCRs) are target of forty percent of clinically used drugs, here we discuss the newly identified cardioprotective agents that bind GPCRs of adrenalin, adenosine, melatonin, ghrelin, galanin, apelin, prokineticin and cannabidiol. (
  • We also discuss whether other drugs in this class are likely to show similar cardiovascular benefits. (
  • Side effect rates for the anticholinergic drugs were compared using univariate (Chi-square) and multivariate (logistic regression) methods.Results The files from the FDA held data for 36 491 different subjects, of whom 2610 (7.15%) experienced a cardiovascular or neurovascular side effect. (
  • Further studies on the association between anticholinergic drugs and cardiovascular and neurovascular side effects are recommended. (
  • The data on cardiovascular benefits are increasing, but as with all powerful drugs, they can't be used in all patients. (
  • A variety of cardiovascular drugs inhibit the paraoxonase 1 enzyme from human serum, indicating that they may have uninteded cardiovascular side effects. (
  • 1- 5 It has been suggested that improvement of insulin sensitivity in these high risk individuals may delay the development of NIDDM and its related cardiovascular complications. (
  • In the PLATO study, the reduction in risk of cardiovascular events appears early and the benefit over clopidogrel grows with time. (
  • As previously reported, the study met its primary safety objective and met the FDA-mandated criteria for cardiovascular safety, finding that long-term treatment with BELVIQ did not increase the incidence of major adverse cardiovascular events (MACE) in overweight and obese patients at high risk for a CV event. (
  • Several clinical studies demonstrate that hyperleptinemia predicts acute cardiovascular events, restenosis after coronary injury such as angioplasty, and cerebral stroke independent of traditional risk factors. (
  • There are many different ways that people attempt to reduce cardiovascular events. (
  • There are some statin alternatives that have been shown to reduce cardiovascular events and reduce risks of coronary disease . (
  • For more information about how adding alternative agent could reduce cardiovascular events, call Brookhaven Heart . (
  • Ultrasound contrast agents (UCAs) have been in the echocardiographic "toolbox" for many years. (
  • Background The frequency, manifestations, and severity of acute adverse reactions associated with gadolinium-based contrast agents in the specific setting of cardiovascular magnetic resonance have not been systematically evaluated yet. (
  • The author reviews clinical trial data on the effect of glucose control on CVD risk, the selection and timing of antihyperglycemic agents, the management of associated CVD risk factors, and strategies to improve patient adherence and acceptance-with the goal of assisting physicians in selecting appropriate management strategies for their patients with T2DM. (
  • Delivering a cardiovascular disease prevention programme in the United Kingdom: translating theory into practice. (
  • A letter to the editor is presented in response to the article concerning the second Joint British Societies (JBS2) Guidelines on cardiovascular disease prevention. (
  • Lenz, TL & Hilleman, DE 2001, ' The role of combination therapy with antiplatelet and oral anticoagulant agents in cardiovascular disease ', P and T , vol. 26, no. 11, pp. 561-562+565. (
  • It has been in use for more than 40 years and is generally an important agent for the treatment of essential hypertension. (
  • While numerous medications have been approved by the FDA for the treatment of hyperglycemia, their cardiovascular safety has been questioned and is the subject of ongoing CV outcome trials (CVOTs). (
  • Nonetheless, acute treatment with the anticholinergic agent atropine and/or the adrenergic agonist isoproterenol may be warranted. (
  • Anti-phospholipid antibodies, neuroleptic treatment and cardiovascular morbidity. (
  • A letter to the editor is presented about the risk of cardiovascular morbidity among patients receiving anti-phospholipid antibodies and neuroleptic treatment. (
  • Despite advances in medical therapies and new treatment modalities for patients with or at risk for cardiovascular disease, health equality and access to care remain significant areas of concern. (
  • Established treatment options for anemia of chronic kidney disease (CKD) are Erythropoietin Stimulating Agents (ESA), including erythropoietins (EPO alfa, beta), darbepoetin (DARBO α), pegylated epoietin (continuous erythropoietin receptor activator, CERA) and biosimilar epoetins. (
  • Procoralan has been discovered and developed by Servier and represents one of the most important advances in cardiovascular treatment over the last two decades. (
  • For this purpose, we compared the effect of the chronic treatment with the AT 1 receptor antagonist losartan (30 mg/kg/day, p.o.) on the cardiovascular and autonomic changes evoked by the heterotypic stressor chronic variable stress (CVS) and the homotypic stressor repeated restraint stress (RRS). (
  • But a health care agent can usually make medical treatment decisions at the end of life or anytime a person is not able to communicate. (
  • The ultimate goals of therapy for cardiovascular disease are achieved when treatment resolves the presenting clinical signs, the respiratory and heart rates are not increased at rest, and quality of life is good for both pet and owner. (
  • These agents are particularly useful in the treatment of supraventricular tachycardias. (
  • In this review, we discuss cardiovascular actions of leptin related to atherosclerosis, insulin resistance, and hypertension. (
  • Conclusion This observational study of recorded side effects showed that, except for stroke and hypertension, patients who were treated with an inhaled anticholinergic drug appeared to be at higher risk of developing neurovascular or cardiovascular side effects, than those treated with an oral drug. (
  • Preliminary trials of long-term therapy with oral verapamil for control of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia suggest that this agent is effective for therapy of these arrhythmias. (
  • We describe our clinical experience with patients who had cardiovascular adverse drug reactions (CVADRs) with combination therapy. (
  • The criterion for rescue therapy by addition of a third oral agent (if in the rosiglitazone group) or transfer to insulin (in the metformin plus sulfonylurea group) was a confirmed HbA 1c of 8.5% or more. (
  • Therapy for cardiovascular disease may include management with medications, interventional or surgical procedures, exercise and diet modifications, or a combination of these therapies. (
  • The attachment of the agent to the enzyme is permanent (unless removed by therapy). (
  • However, while the OP pesticides cause the same biological effects as nerve agents, there are some important differences in the duration of biological activity and response to therapy. (
  • However, because both agents exert a negative chronotropic effect, their combined use may cause bradyarrhythmias with resultant symptoms of cerebral, coronary, and systemic hypoperfusion. (
  • Therefore, the present study investigated the involvement of angiotensin II (Ang II) acting on the type 1 Ang II receptor (AT 1 ) in the cardiovascular dysfunctions evoked by both homotypic and heterotypic chronic emotional stresses in rats. (
  • The primary endpoint was cardiovascular hospitalisation or cardiovascular death, with a hazard ratio (HR) non-inferiority margin of 1.20. (
  • Early examination of the CV risks and benefits of common medications revealed mixed results depending on the agent tested. (
  • Previous meta-analyses assessing the cardiovascular risks of macrolides reported conflicting results ( 3 , 8 , 9 ). (
  • Furthermore, initial concerns (now largely refuted [ 4 ]) about the cardiovascular safety of rosiglitazone led the US Food and Drug Administration to mandate that all new glucose-lowering agents must be tested for cardiovascular safety in post-marketing endpoint trials. (
  • Hypoglycemic agents and potential anti-inflammatory activity. (
  • Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes. (
  • Prendergast BD "Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. (
  • It may be necessary to use antiarrhythmic agents for concomitant tachyarrhythmia. (
  • Many attempts have been made to classify antiarrhythmic agents. (
  • The problem arises from the fact that many of the antiarrhythmic agents have multiple modes of action, making any classification imprecise. (
  • The five main classes in the Vaughan Williams classification of antiarrhythmic agents are: Class I agents interfere with the sodium (Na+) channel. (
  • The class I antiarrhythmic agents interfere with the sodium channel. (
  • Debabrata Mukherjee, M.D is the Chairman of the Department of Internal Medicine and the Program Director for the Cardiovascular Medicine Fellowship program at the Texas Tech University Health Sciences Center at El Paso. (
  • Dr. Christopher P. Cannon , is an Associate Professor of Medicine at Harvard Medical School and an Associate Physician in the Cardiovascular Division at Brigham and Women's Hospital in Boston, Massachusetts. (
  • Patients with impaired liver and/or renal function treated with sulfonylureas may be exposed to higher serum drug concentrations, which can increase the potential for severe hypoglycemic episodes induced by these agents. (
  • Several glucose lowering agents have been shown to influence the restenosis process and thus the outcome after PCI. (
  • However, no large trials have been undertaken in which the effect of glucose lowering agents on restenosis is associated with improved outcome. (
  • Since these first trials, numerous antidiabetic agents have been approved in the U.S. (
  • Class IV agents are slow non-dihydropyridine calcium channel blockers. (
  • Presents a letter to the editor in response to the article "A Quantitative Assessement of Plasma Homocysteine as a Risk Factor for Cardiovascular Disease," by C. J. Boushey and colleagues published in a 1995 issue of the "Journal of American Medical Association. (
  • The Multiple Risk Factor Intervention Trial (MRFIT), which involved ∼ 360,000 men, showed that for every 38-mg/dl decrease in total cholesterol, there was a 50% decrease in death from cardiovascular causes. (
  • Other cardiovascular or metabolic variables did not change significantly compared with placebo during follow up. (
  • In this prospective randomised double blind study, the long term effects of glipizide and metformin on multiple cardiovascular variables, metabolic parameters, and lipid profile in non-diabetic individuals with insulin resistance and a family history of NIDDM were studied. (
  • Propranolol (Inderal), a β -adrenergic blocking agent, simultaneously improves metabolic processes in the heart and reduces the contractile activity of the myocardium. (
  • Fish oils in addition to a Mediterranean-type diet has been shown to reduce cardiovascular risk. (
  • However, it has since been associated with the risk of cardiovascular death ( 5 ). (
  • Despite the fact that cardiovascular disease (CVD) is the number one cause of death globally, investment in drug development and new drug approvals for CVD are precipitously declining. (
  • Despite improvements in death rates from cardiovascular disease (CVD) around the world, CVD remains a leading cause of death and ill health in the UK, where death rates are amongst the highest in the world. (